Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

MDWD


Top 10 Correlated ETFs

MDWD


Top 10 Correlated Stocks

MDWD


In the News

12:31 03 Oct 2022 MDWD

MediWound Ltd. (MDWD) CEO Ofer Gonen on Q2 2022 Results - Earnings Call Transcript

MediWound Ltd. (NASDAQ:MDWD ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Monique Kosse - Investor Relations Ofer Gonen - Chief Executive Officer Boaz Gur-Lavie - Chief Financial Officer Conference Call Participants Bryan Bergin - Cowen Ryan Zimmerman - BTIG Arthur He - H.C.

08:00 03 Oct 2022 MDWD

MediWound Schedules Second Quarter 2022 Financial Results

Conference Call and Webcast Scheduled for Tuesday, August 9, 2022 at 8:30 AM ET Conference Call and Webcast Scheduled for Tuesday, August 9, 2022 at 8:30 AM ET

12:04 03 Oct 2022 MDWD

MediWound Ltd. (MDWD) CEO Sharon Malka on Q1 2022 Results - Earnings Call Transcript

MediWound Ltd. (NASDAQ:MDWD ) Q1 2022 Earnings Conference Call May 17, 2022 8:30 AM ET Company Participants Monique Kosse - IR Sharon Malka - CEO Boaz Gur-Lavie - Chief Financial Officer Ofer Gonen - Board Member Lior Rosenberg - Chief Medical Officer Cyaandi R.

09:47 03 Oct 2022 MDWD

MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates

MediWound (MDWD) delivered earnings and revenue surprises of -9.09% and 1.31%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

07:37 03 Oct 2022 MDWD

MediWound Posts Promising EscharEx Data For Chronic Wounds

MediWound Ltd (NASDAQ: MDWD) has announced results from its U.S. Phase 2 clinical study of EscharEx for the debridement of venous leg ulcers (VLUs).  The study met its primary and secondary endpoints and wound closure safety measurements.

04:01 03 Oct 2022 MDWD

MediWound to Report First Quarter Financial Results and Host a Conference Call and Webcast on May 17, 2022

YAVNE, Israel, May 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the first quarter ended March 31, 2022 on Tuesday, May 17, 2022.

08:00 03 Oct 2022 MDWD

MediWound to Present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SAWC) Spring 2022

Results Highlight the Safety and Efficacy in Hard-to-Heal Wounds

12:31 03 Oct 2022 MDWD

MediWound Ltd. (MDWD) CEO Sharon Malka on Q4 2021 Results - Earnings Call Transcript

MediWound Ltd. (MDWD) CEO Sharon Malka on Q4 2021 Results - Earnings Call Transcript

09:47 03 Oct 2022 MDWD

MediWound (MDWD) Reports Q4 Loss, Misses Revenue Estimates

MediWound (MDWD) delivered earnings and revenue surprises of 6.25% and 2.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

08:00 03 Oct 2022 MDWD

MediWound to Report Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call and Webcast on March 17, 2022

YAVNE, Israel, March 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the fourth quarter and year ended December 31, 2021 on Thursday, March 17 2022.

Financial details

Company Rating
Neutral
Market Cap
56.6M
Income
-14.29M
Revenue
22.32M
Book val./share
0.07
Cash/share
-
Dividend
-
Dividend %
-
Employees
77
Optionable
No
Shortable
Yes
Earnings
14 Nov 2022
P/E
-2.8
Forward P/E
-2.44
PEG
-0.56
P/S
1.79
P/B
20.53
P/C
-
P/FCF
-3.79
Quick Ratio
0.28
Current Ratio
1.95
Debt / Equity
0.64
LT Debt / Equity
0.64
-
-
EPS (TTM)
-0.51
EPS next Y
-0.57
EPS next Q
-0.14
EPS this Y
46.48%
EPS next Y
10.78%
EPS next 5Y
10.78%
EPS last 5Y
-12.12%
Revenue last 5Y
56.94%
Revenue Q/Q
-19.68%
EPS Q/Q
-20%
-
-
-
-
SMA20
-26.26%
SMA50
-17.05%
SMA100
-23.56%
Inst Own
0%
Inst Trans
0%
ROA
-54%
ROE
4265%
ROC
-0.83%
Gross Margin
35%
Oper. Margin
-56%
Profit Margin
-64%
Payout
-
Shs Outstand
40.72M
Shs Float
22.43M
-
-
-
-
Target Price
-
52W Range
1.21-4.01
52W High
-65.25%
52W Low
+39%
RSI
27.16
Rel Volume
1.13
Avg Volume
122.23K
Volume
138.02K
Perf Week
-20.57%
Perf Month
-34.74%
Perf Quarter
-36.53%
Perf Half Y
-29.44%
-
-
-
-
Beta
0.961246
-
-
Volatility
0.02%, 0.24%
Prev Close
-0.71%
Price
1.39
Change
2.21%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
0.110.131.170.80.87
Net income per share
-0.95-0.040.18-0.34-0.5
Operating cash flow per share
-0.7-0.450.3-0.25-0.33
Free cash flow per share
-0.75-0.470.28-0.29-0.35
Cash per share
1.550.871.080.790.41
Book value per share
0.410.330.560.27-0.17
Tangible book value per share
0.380.310.540.25-0.18
Share holders equity per share
0.410.330.560.27-0.17
Interest debt per share
-0.02-0.030.050.030.08
Market cap
106.79M130.69M83.44M131.42M60.68M
Enterprise value
70.72M123.97M78.2M114.05M51.02M
P/E ratio
-4.82-123.6416.84-14.29-4.48
Price to sales ratio
42.7838.432.626.042.55
POCF ratio
-6.49-10.7510.07-19.06-6.81
PFCF ratio
-6.09-10.311.13-16.81-6.45
P/B Ratio
11.114.575.518.07-13.24
PTB ratio
11.114.575.518.07-13.24
EV to sales
28.3336.452.465.242.15
Enterprise value over EBITDA
-3.21-92.3114.03-15.68-4.48
EV to operating cash flow
-4.3-10.29.43-16.54-5.72
EV to free cash flow
-4.03-9.7710.43-14.59-5.43
Earnings yield
-0.21-0.010.06-0.07-0.22
Free cash flow yield
-0.16-0.10.09-0.06-0.15
Debt to equity
000.130-0.3
Debt to assets
0.780.750.630.771.23
Net debt to EBITDA
1.645-0.942.390.85
Current ratio
7.646.683.433.171.39
Interest coverage
32.514.59-8.48-10.63-12.43
Income quality
0.7411.51.670.750.66
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
1.491.10.160.250.26
Research and developement to revenue
2.175.250.310.350.43
Intangibles to total assets
0.010.010.010.010.02
Capex to operating cash flow
0.070.04-0.10.130.05
Capex to revenue
-0.43-0.16-0.02-0.04-0.02
Capex to depreciation
-1.9-0.93-0.69-0.85-0.39
Stock based compensation to revenue
0.550.190.040.060.07
Graham number
2.970.541.511.431.37
ROIC
-0.35-0.130.15-0.39-1.24
Return on tangible assets
-0.51-0.030.12-0.3-0.7
Graham Net
0.220.130.30.02-0.4
Working capital
36.09M27.82M25.26M17.93M4.23M
Tangible asset value
8.99M8.48M14.74M6.91M-4.88M
Net current asset value
7.01M6.41M10.21M2.4M-9.37M
Invested capital
000.130-0.3
Average receivables
3.14M5.05M3.7M2.84M2.55M
Average payables
0002.99M3.84M
Average inventory
1.63M1.53M1.5M1.38M1.29M
Days sales outstanding
502.46780.0152.3247.6334.82
Days payables outstanding
00076.81114.26
Days of inventory on hand
436.24293.6849.6935.4329.22
Receivables turnover
0.730.476.987.6610.48
Payables turnover
0004.753.19
Inventory turnover
0.841.247.3510.312.49
ROE
-2.3-0.120.33-1.262.96
Capex per share
-0.05-0.02-0.03-0.03-0.02

Quarterly Fundamentals Overview

Last date of statement is 2022-03-31 for Q1

Metric History 2021-03-312021-06-302021-09-302021-12-31 2022-03-31
Revenue per share
0.210.230.230.20.15
Net income per share
-0.1-0.12-0.12-0.15-0.12
Operating cash flow per share
-0.11-0.04-0.1-0.08-0.14
Free cash flow per share
-0.11-0.04-0.11-0.09-0.15
Cash per share
00.6400.410
Book value per share
0.180.08-0.03-0.170.07
Tangible book value per share
0.160.07-0.04-0.180.06
Share holders equity per share
0.180.08-0.03-0.170.07
Interest debt per share
0.030.080.070.020.05
Market cap
146.26M101.97M90.98M64.31M57.18M
Enterprise value
146.26M86.58M92.47M54.65M58.42M
P/E ratio
-12.83-7.98-6.8-3.86-3.98
Price to sales ratio
25.0116.8414.2811.7212.97
POCF ratio
-50.21-103.53-32.29-28.77-14.07
PFCF ratio
-46.71-100.86-30.87-27.35-13.53
P/B Ratio
30.3748.15-110.82-14.0329.4
PTB ratio
30.3748.15-110.82-14.0329.4
EV to sales
25.0114.2914.519.9613.26
Enterprise value over EBITDA
-89.35-35.23-36.28-11.77-19.72
EV to operating cash flow
-50.21-87.9-32.81-24.45-14.37
EV to free cash flow
-46.71-85.64-31.38-23.25-13.83
Earnings yield
-0.02-0.03-0.04-0.06-0.06
Free cash flow yield
-0.02-0.01-0.03-0.04-0.07
Debt to equity
00.76-1.81-0.30.64
Debt to assets
0.840.921.041.230.93
Net debt to EBITDA
06.26-0.582.08-0.42
Current ratio
2.412.231.871.391.95
Interest coverage
-2.04-7.26-6.314.6-10.91
Income quality
1.020.310.840.541.13
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00.29000
Research and developement to revenue
0.380.440.450.450.55
Intangibles to total assets
0.010.010.010.020.01
Capex to operating cash flow
0.070.030.050.050.04
Capex to revenue
-0.040-0.02-0.02-0.04
Capex to depreciation
-0.8-0.08-0.39-0.42-0.5
Stock based compensation to revenue
0.070.080.060.070.08
Graham number
0.650.460.290.760.44
ROIC
-0.1-0.17-0.22-0.39-0.22
Return on tangible assets
-0.1-0.12-0.15-0.21-0.14
Graham Net
-0.73-0.16-0.76-0.4-0.73
Working capital
14.59M11.86M8.71M4.23M10.71M
Tangible asset value
4.47M1.79M-1.14M-4.88M1.66M
Net current asset value
28K-2.57M-5.32M-9.37M-2.47M
Invested capital
00.76-1.81-0.30.64
Average receivables
3.92M2.61M2.91M2.27M2.73M
Average payables
3.98M4.38M4.2M4.69M5.16M
Average inventory
1.34M1.3M1.23M1.2M1.56M
Days sales outstanding
85.843.850.1837.1865.35
Days payables outstanding
85.4698.8685.24106.98171.72
Days of inventory on hand
38.5634.0228.7727.3658.64
Receivables turnover
1.052.051.792.421.38
Payables turnover
1.050.911.060.840.52
Inventory turnover
2.332.653.133.291.53
ROE
-0.59-1.514.070.91-1.85
Capex per share
-0.01000-0.01

Frequently Asked Questions

What is MediWound Ltd. stock symbol ?

MediWound Ltd. is a IL stock and trading under the symbol MDWD

What is MediWound Ltd. stock quote today ?

MediWound Ltd. stock price is $1.39 today.

Is MediWound Ltd. stock public?

Yes, MediWound Ltd. is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap